Please login to the form below

CAR therapies

This page shows the latest CAR therapies news and features for those working in and with pharma, biotech and healthcare.

BMS and bluebird bio gain FDA approval for multiple myeloma therapy

Abecma is a CAR T cell therapy approved for pre-treated myeloma patients. ... Samit Hirawat, chief medical officer, BMS said: “CAR T cell therapies have shown transformational potential for the treatment of haematologic malignancies and we, with our

Latest news

bluebird bio posts modest Q4 revenue growth as it continues investigation into troubled LentiGlobin

BMS) and monetisation for ex-US milestones and royalties from CAR T cell therapies ide-cel and bb21217.
FDA approves BMS’ blood cancer CAR T therapy after delay

Breyanzi joins other approved CAR T therapies on the market from Gilead/Kite and Novartis. ... BMS, Novartis and Gilead/Kite’s respective CAR T therapies all carry a black box warning for neurotoxicity, as well as cytokine release syndrome – an
Relics from the past

In oncology, CAR-T therapies involve such complex approaches that they can hardly just be called drugs anymore. ... We may still be calling companies ‘pharma’ when their gene therapies hardly count as pharmaceuticals.
Kite and Oxford BioTherapeutics sign oncology research pact

Selecting the right target is fundamental for the successful development of first-in-class cell therapies. ... In 2017, Gilead paid $11.9bn to acquire Kite and its pipeline of chimeric antigen receptor T cell (CAR-T) therapies.
FDA delays BMS’ liso-cel decision, citing COVID-19 travel restrictions

BMS also agreed similar conditional payments, dependent on approval, for Celgene’s multiple sclerosis therapy Zeposia (ozanimod) and another CAR-T therapy, ide-cel (idecabtagene vicleucel). ... therapies. The CAR-T therapy targets CD19, a protein which

More from news
Approximately 1 fully matching, plus 92 partially matching documents found.

Latest Intelligence

Sourcing R&D innovation: why pharma companies need to evolve their business models

Historically, both large pharmaceutical and small biotechnology companies have relied on both internal and external sourcing of innovative and promising therapies. ... and. CAR-T therapies. Gilead’s acquisition of Kite Pharma and Bristol-Myers
The impact of COVID-19 on clinical trials

impact on the initiation and completion of hundreds of clinical trials involving investigational therapies for many serious diseases. ... Therapy mechanism of action – immunosuppressive therapies and therapies that require complex and prolonged
Cortellis Drugs to Watch in 2020 report

Thanks to the CAR construct, the engineered T cells can recognise and attack the CD19-expressing cancer cells. ... This composition could confer efficacy and safety advantages, including fewer adverse effects such as cytokine release syndrome (CRS) and
China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances

At the spear point is China’s emergence as the epicentre of biotech research and development, with its performance on CAR-T therapies turning heads. ... We are introducing the international best practices of developing CAR T to our China team and
European biotech: a new generation of leaders emerges

year. The promise of the molecule is great, with analysts seeing it as a possible challenge to Novartis and Gilead’s CAR-T therapies. ... This means its clinical outcomes could match those seen in the CAR-Ts, but without the complexity and cost of

More from intelligence
Approximately 0 fully matching, plus 28 partially matching documents found.

Latest appointments

Health comms agency emotive hires new cell and gene therapy leader

It is also charged with developing HCP engagement on gene silencing technology and educating on cell therapies such as CAR-T, and the new business unit will provide core expertise in ... He says this will be needed to ensure advanced therapies realise
Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more

Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

The heavy toll of COVID-19 on cancer patients

For example, all CAR-T cell therapies were paused as intensive care unit beds were needed to help COVID-19 patients recover. ... New therapies that minimize hospital visits may have to be prioritized by pharmaceuticals and MedTech companies.
In the precision medicine era, the line between products and services is blurred

Instead, we carried out in-depth interviews with different types of stakeholders who had considerable experience working on early CAR-T therapies and clinical trials. ... Both of these scenarios were true in the case of the CAR-T treatment.
Precision paediatrics: Treating patients with CAR-T

It’s an exciting time for CAR-T therapy. SA: It’s an integrated, holistic approach. ... This approach can make targeted therapies like CAR-T a reality. A good example at GOSH is in bone marrow transplants.
Highlights in haematologic malignancy from ASH 2018

However, CAR T-cell therapies stop working in some patients and severe toxicity can also occur. ... Other abstracts reported on CAR T-cell therapies for multiple myeloma directed against the B-cell maturation antigen (BCMA).
Download our infographic: Addressing the biggest challenges for rare disease communities

Recently these have included advanced genetic therapies, such as viral mediated gene transfer and CAR-T therapies.

More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Senior Content Editor - Biotechnology: Salary TBC

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Principal Medical Writer: Varies on experience

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Account Management: Competitive Salary Offered

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

PMHub

Add my company

Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?: The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.: Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....